Puhe Biopharma

Focus: Puhe Biopharma is a China-based oncology-focused biotech company developing small molecule therapeutics, positioned in the competitive Asian oncology market.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Puhe Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Puhe Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

YK-029A

Treatment

PHASE_1_2

Clinical Trials (1)

NCT05767866Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Phase 1/2

Help build intelligence for Puhe Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to early-stage oncology programs with Phase 1/2 and Phase 3 assets in high-unmet-need areas like NSCLC
Ground-floor role at a China-based biotech with potential for rapid scaling as programs advance
Focused pipeline strategy in small molecules targeting validated oncology pathways

Watch Out For

Pre-revenue stage with unknown funding, cash position, and financial runway—stability uncertain
Limited public disclosure on employee count, founding date, and company financials raises transparency concerns
Only 15 active job openings suggest modest hiring velocity and potentially constrained growth trajectory

Generated by Claude from Puhe Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PH009-1 tablet

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE_1_2

Clinical Trials (1)

NCT06590194PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 1/2

YK-209A tablet

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE_3

Clinical Trials (1)

NCT05767892YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo